Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Am Heart J ; 136(2): 335-44, 1998 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9704699

RESUMEN

BACKGROUND: The aim of the study was to determine whether the recovery of global and regional left ventricular function after successful percutaneous transluminal angioplasty (PTCA) could be predicted by measuring coronary flow reserve before performing the intervention. METHODS AND RESULTS: Thirty-two patients underwent PTCA 6.9 +/- 3.4 days after a recent myocardial infarction. Coronary flow reserve was determined in the infarct-related artery before PTCA by using an intracoronary Doppler tipped wire. Global and regional wall motion were determined by 2-dimensional echocardiography before the Flowire study and again 7 weeks after the angioplasty. Whereas the global and regional wall motion score indices improved in 20 patients (recovery group), they deteriorated or did not change in 9 patients (nonrecovery group). Coronary flow reserve distal to the lesion in the infarct-related artery was significantly higher in the recovery group (1.43 +/- 0.57 vs 0.98 +/- 0.70, P = .0001). Coronary flow reserve distal to the lesion in the infarct-related artery was < 1.1 in patients whose global or regional left ventricular function did not improve at follow-up, whereas flow reserve ranged between 1.1. and 1.8 while patients in whom left ventricular function improved. CONCLUSIONS: These results suggest that the absence of inducible coronary flow reserve may predict failure of left ventricular systolic function to improve between the first and sixth week after infarction. Measurement of flow reserve with a Flowire at the time of diagnostic angiography after recent myocardial infarction may ultimately prove helpful in deciding whether to proceed with revascularization.


Asunto(s)
Angioplastia Coronaria con Balón , Circulación Coronaria/fisiología , Infarto del Miocardio/fisiopatología , Función Ventricular Izquierda/fisiología , Adulto , Anciano , Circulación Colateral/fisiología , Angiografía Coronaria , Ecocardiografía , Ecocardiografía Doppler , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/diagnóstico por imagen , Infarto del Miocardio/terapia , Pronóstico , Resultado del Tratamiento , Ultrasonografía Intervencional
2.
Artículo en Chino | MEDLINE | ID: mdl-10074307

RESUMEN

In order to investigate the therapeutic effect of N-2-Mercaptopropionyl-glycine (MPG), a scavenger of hydroxyl radical, on postischemic myocardial dysfunction of 39 conscious unsedated dogs were undergone a 15 min occlusion of left anterior descending coronary artery followed by 48 hours of reperfusion. The treated dogs (n = 17) received an infusion of MPG (100 mg/kg.h) for 60 minutes (starting 15 minutes before occlusion) while the control dogs (n = 22) received normal saline. The result showed that there were no significant differences between the two groups in collateral blood flow determined by radioactive microsphere, occlusion vascular bed and hemodynamic variables. Systolic thickening fraction of ventricular wall (an index of regional myocardial function) was similar in both groups under baseline condition and during ischemia, whereas it (expressed as percent of baseline) was considerably greater in treated dogs at 2, 3, 4, 5, 6 hours of reperfusion. Much more significant recovery was observed in the dogs with collateral flow less than 10% in MPG group. The exponential regression analysis showed that the lower the collateral flow, the greater the recovery of function in treated dogs. It is concluded that MPG improves recovery of myocardial function after reversible regional ischemia, especially with lower collateral blood flow.


Asunto(s)
Depuradores de Radicales Libres/farmacología , Daño por Reperfusión Miocárdica/fisiopatología , Aturdimiento Miocárdico/fisiopatología , Tiopronina/farmacología , Animales , Circulación Colateral , Perros , Femenino , Masculino
3.
Circ Res ; 76(1): 82-94, 1995 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8001281

RESUMEN

Recent evidence suggests a cardioprotective effect of adenosine in myocardial ischemia and reperfusion. The present study was undertaken to determine (1) whether adenosine attenuates myocardial stunning, (2) if so, whether the beneficial effect of adenosine takes place during ischemia or after reperfusion, and (3) whether adenosine preconditions against myocardial stunning. A total of 93 dogs were used. In phase A of the study, open-chest dogs undergoing a 15-minute occlusion of the left anterior descending coronary artery followed by 4 hours of reperfusion received an intracoronary infusion of either saline (group I [control], n = 14), 2 mg/min adenosine from 30 minutes before occlusion until 1 hour after reperfusion (group II, n = 10), or 2 mg/min adenosine from 2 minutes before reperfusion until 1 hour after reperfusion (group III, n = 11). Regional myocardial function (assessed as systolic wall thickening) was similar in the three groups at baseline and during ischemia. After reperfusion, dogs treated with adenosine before, during, and after ischemia (group II) demonstrated a significant improvement in the recovery of function that persisted throughout the 4 hours of reperfusion. In contrast, in dogs treated only during the reperfusion period (group III), the recovery of function was not statistically different from that in control dogs. The enhanced recovery effected by adenosine in group II could not be ascribed to differences in ischemic zone size, collateral flow during occlusion, coronary flow after reperfusion, arterial pressure, heart rate, or other hemodynamic variables. In phase B of the study, dogs received an intracoronary infusion of either saline (group IV [control], n = 6) or adenosine (4 mg/min from 40 to 10 minutes before occlusion [group V, n = 6]). Despite pretreatment with adenosine, the recovery of function in group V was indistinguishable from that in the control group. This study demonstrates that (1) continuous administration of adenosine before, during, and after ischemia results in a significant and sustained attenuation of myocardial stunning; (2) this improved recovery of function cannot be attributed to nonspecific variables, such as collateral flow during coronary occlusion, coronary flow after reperfusion, or other hemodynamic factors, and therefore reflects a direct cardioprotective action of adenosine; (3) the protection against stunning is lost or markedly diminished if adenosine is given only at reperfusion; and (4) administration of adenosine before ischemia does not precondition the myocardium against the stunning induced by a 15-minute occlusion.(ABSTRACT TRUNCATED AT 400 WORDS)


Asunto(s)
Adenosina/farmacología , Aturdimiento Miocárdico/fisiopatología , Adenosina/uso terapéutico , Animales , Circulación Coronaria/efectos de los fármacos , Perros , Femenino , Hemodinámica/efectos de los fármacos , Masculino , Daño por Reperfusión Miocárdica/prevención & control , Aturdimiento Miocárdico/tratamiento farmacológico , Receptores Purinérgicos P1/fisiología
4.
Circulation ; 88(5 Pt 1): 2359-69, 1993 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-8222129

RESUMEN

BACKGROUND: Mounting evidence suggests a protective effect of exogenous adenosine in myocardial ischemia and reperfusion. We tested the hypothesis that augmentation of endogenous adenosine levels, achieved by inhibiting adenosine catabolism and washout, is beneficial in postischemic myocardial dysfunction ("stunning"). METHODS AND RESULTS: In phase I of the study, open-chest dogs undergoing a 15-minute coronary artery occlusion and 4 hours of reperfusion received an intracoronary infusion of either saline (controls, n = 23) or 6-(4-nitrobenzyl)-mercapto: purine ribonucleoside (NBMPR, a selective nucleoside transport inhibitor) combined with erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA, a potent adenosine deaminase inhibitor) (EHNA + NBMPR, n = 15) starting 15 minutes before coronary occlusion and ending 15 minutes after the initiation of reflow. Regional myocardial function (assessed as systolic wall thickening) was similar in control and treated groups at baseline and during ischemia. After reperfusion, however, the dogs treated with EHNA + NBMPR exhibited a significant improvement in the recovery of function, which was evident as early as 30 minutes after restoration of flow and was sustained throughout the rest of the reperfusion phase. The enhanced recovery effected by EHNA + NBMPR could not be attributed to nonspecific factors such as differences in collateral flow during occlusion, coronary flow after reperfusion, arterial pressure, heart rate, or other hemodynamic variables. In phase II of the study, the myocardial content of adenine nucleotides and nucleosides was measured by high performance liquid chromatography in myocardial biopsies obtained serially from open-chest dogs undergoing the same protocol used in phase I. There were no significant differences between control (n = 8) and treated (n = 9) dogs with respect to myocardial levels of adenosine triphosphate (ATP) at 30 and 60 minutes after reperfusion, indicating that the beneficial effects of EHNA + NBMPR cannot be ascribed to repletion of ATP stores. Compared with controls, dogs treated with EHNA + NBMPR exhibited a much larger increase in myocardial adenosine (6.07 +/- 1.47 vs 1.03 +/- 0.16 nmol/mg protein, P < .05) and a much smaller increase in inosine (0.52 +/- 0.27 vs 3.04 +/- 0.54 nmol/mg protein, P < .05) at the end of ischemia, such that the inosine-to-adenosine ratio noted in controls was completely reversed (approximately 6:1 vs approximately 1:6, respectively). In the treated group, adenosine levels remained markedly increased compared with controls up to 1 hour after reperfusion. CONCLUSIONS: This study demonstrates that (1) administration of an adenosine deaminase inhibitor plus a nucleoside transport blocker is remarkably effective in augmenting myocardial adenosine levels during regional ischemia and subsequent reperfusion in vivo, (2) this augmentation of adenosine results in a significant and sustained attenuation of myocardial stunning, and (3) the attenuation of stunning is not due to ATP repletion or to nonspecific actions on hemodynamic variables or coronary flow. These findings suggest that endogenous adenosine production during ischemia serves as an important pathophysiological mechanism that protects against myocardial stunning. The results also suggest that augmentation of endogenous adenosine (without exogenous adenosine administration) represents an effective therapeutic approach to the alleviation of reversible postischemic dysfunction.


Asunto(s)
Adenosina/metabolismo , Circulación Coronaria/fisiología , Aturdimiento Miocárdico , Adenina/análogos & derivados , Adenina/farmacología , Nucleótidos de Adenina/metabolismo , Animales , Perros , Corazón/efectos de los fármacos , Corazón/fisiopatología , Hemodinámica/efectos de los fármacos , Hemodinámica/fisiología , Contracción Miocárdica/efectos de los fármacos , Isquemia Miocárdica/metabolismo , Reperfusión Miocárdica , Nucleósidos/metabolismo , Tioinosina/análogos & derivados , Tioinosina/farmacología
5.
Circ Res ; 73(4): 705-23, 1993 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8396504

RESUMEN

Recent studies suggest that the hydroxyl radical (.OH) plays a pathogenetic role in postischemic ventricular dysfunction (myocardial "stunning"). This concept, however, is predicated exclusively on results obtained in anesthetized open-chest preparations, which are subject to the confounding influence of many unphysiological conditions and in which both myocardial stunning and free radical generation are greatly exaggerated. The lack of supporting evidence in more physiological animal models represents a major limitation of the .OH hypothesis of stunning. Furthermore, concern has been raised that myocardial stunning may be a period of "rest" necessary for full recovery, so that attenuation of the early phase of stunning by antioxidant therapy may have subsequent detrimental effects on the resting function and/or on the return of myocardial contractile reserve. To address these issues, in phase 1 of this study conscious unsedated dogs undergoing a 15-minute coronary artery occlusion received an intravenous infusion of normal saline (n = 22), of the .OH scavenger N-2-mercaptopropionyl glycine (MPG, n = 17), or of the iron chelator desferrioxamine (DF, n = 14). Compared with control dogs, the dogs treated with MPG or DF exhibited significantly greater postischemic wall thickening throughout the first 6 hours of reperfusion; the total deficit of wall thickening during this time interval was reduced 50% by MPG and 50% by DF. The magnitude of this beneficial effect was a function of the severity of ischemia, so that the dogs with the lowest collateral flows had the greatest improvement of wall thickening. The accelerated recovery produced by MPG and DF in the first 6 hours was not followed by any deterioration of resting wall thickening at 24 or 48 hours. Furthermore, in dogs treated with MPG or DF, the increase in wall thickening elicited by maximal inotropic stimulation (isoproterenol or dopamine) was similar before stunning and shortly after resting wall thickening had normalized (24 or 48 hours after reflow); thus, despite the fact that most of the early postischemic dysfunction had been eliminated by antioxidant therapy, there was no subsequent impairment of either resting function or contractile reserve. In phase 2, production of free radicals (measured with the spin trap alpha-phenyl N-tert-butyl nitrone) was markedly (> 80%) inhibited by the same doses of MPG and DF that attenuated stunning in phase 1.(ABSTRACT TRUNCATED AT 400 WORDS)


Asunto(s)
Hidróxidos/toxicidad , Isquemia Miocárdica/fisiopatología , Función Ventricular Izquierda , Animales , Circulación Coronaria/efectos de los fármacos , Deferoxamina/farmacología , Perros , Femenino , Hemodinámica/efectos de los fármacos , Radical Hidroxilo , Masculino , Contracción Miocárdica/efectos de los fármacos , Oxígeno/metabolismo , Tiopronina/farmacocinética , Tiopronina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA